Rituximab is a genetically engineered chimeric murine/human monoclonal antibody that targets CD20, a B-cell-specific surface antigen. It was the first monoclonal anti-CD20 antibody to be approved for

medical use in human diseases. It was initially licensed for non-Hodgkin‟s lymphoma and then made available for chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis. RTX was also successfully used off-label to treat neuromyelitis optica spectrum disorders, MS, myasthenia gravis, autoimmune encephalitis, autoimmune neuropathies, and myopathies.

Rituxan

[1] Rituximab. In: Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US); July 20, 2020.

[2] Tian X, Chen C, Ma L, et al. Efficacy and safety of rituximab in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis [published online ahead of print, 2020 Jul 10]. J Neuroimmunol. 2020;347:577317. doi:10.1016/j.jneuroim.2020.577317